ezetimibe has been researched along with eicosapentaenoic acid ethyl ester in 6 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (eicosapentaenoic acid ethyl ester) | Trials (eicosapentaenoic acid ethyl ester) | Recent Studies (post-2010) (eicosapentaenoic acid ethyl ester) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 421 | 99 | 262 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Castaldo, RS | 1 |
| Habe, K; Higashiyama, A; Mizutani, H; Omoto, Y; Yamanaka, K; Yokoyama, T | 1 |
| Anderson, TJ; Barry, AR; Couture, P; Dayan, N; Francis, GA; Genest, J; Grégoire, J; Grover, SA; Gupta, M; Hegele, RA; Lau, D; Leiter, LA; Leung, AA; Lonn, E; Mancini, GBJ; Manjoo, P; McPherson, R; Ngui, D; Pearson, GJ; Piché, ME; Poirier, P; Sievenpiper, J; Stone, J; Thanassoulis, G; Ward, R; Wray, W | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Di Costanzo, A; Esposito, G; Indolfi, C; Sorrentino, S; Spaccarotella, CAM | 1 |
1 review(s) available for ezetimibe and eicosapentaenoic acid ethyl ester
| Article | Year |
|---|---|
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Ezetimibe; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Proprotein Convertase 9; Triglycerides | 2023 |
5 other study(ies) available for ezetimibe and eicosapentaenoic acid ethyl ester
| Article | Year |
|---|---|
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Topics: Aged; Azetidines; Eicosapentaenoic Acid; Esters; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; New York; Random Allocation; Retrospective Studies | 2014 |
Flutamide-induced photoleukomelanoderma.
Topics: Administration, Cutaneous; Aged; Androgen Antagonists; Benzimidazoles; Biopsy; Biphenyl Compounds; Bisoprolol; Clopidogrel; Drug Eruptions; Eicosapentaenoic Acid; Ezetimibe; Flutamide; Glucocorticoids; Humans; Male; Patch Tests; Photosensitivity Disorders; Prostatic Neoplasms; Skin Pigmentation; Sunlight; Tetrazoles; Ticlopidine; Ursodeoxycholic Acid; Withholding Treatment | 2016 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Pregnancy; Pregnancy Complications; Primary Prevention; Risk Assessment; Secondary Prevention | 2021 |
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |